APOE4 Variant Linked to Greater Neurological Damage in Multiple Sclerosis
A UK Biobank study of 188 multiple sclerosis patients reveals that carriers of the APOE4 gene variant experience significantly greater neurodegeneration than non‑carriers. APOE4 carriers showed higher blood levels of neurofilament light chain and glial fibrillary acidic protein, more extensive brain tissue loss on MRI, and thinner retinal nerve fibers. Cognitive testing also indicated slower processing speed among carriers. The findings position APOE4 as a genetic modifier that can worsen MS severity and influence long‑term outcomes.
Neurologist Ludwig Kappos Awarded Dystel Prize for MS Research Advances
Neurologist Ludwig Kappos received the 2026 John Dystel Prize, a $40,000 award jointly presented by the National MS Society and the American Academy of Neurology. The honor will be conferred at the AAN annual meeting in Chicago, where he will...
Exeter Study Explores Social Camouflaging in Acquired Brain Injury
University of Exeter researchers have launched a study to determine whether people living with acquired brain injury (ABI) employ social camouflaging strategies. Led by MSc student Faye Brookes and Associate Professor Anna Adlam, the project will use a 20‑30 minute...
Tick-Borne Encephalitis Study Identifies ABCG1 as Potential Target for Future Treatments
Researchers at the Medical University of Graz conducted one of the largest genome‑wide association studies on tick‑borne encephalitis (TBE), analyzing about 1,600 patients from multiple European nations. The study pinpointed variants in the cholesterol‑transport gene ABCG1 as a genetic risk...
Restless Legs Syndrome Risk Higher in People with Multiple Sclerosis, Study Finds
A Spanish study of 440 MS patients and 241 matched controls found restless legs syndrome (RLS) twice as common in MS. Confirmed RLS prevalence was 15.2% among MS patients versus 7.9% in controls. Pyramidal symptoms and family history raised RLS...
CHMP Backs Expanded Indications for Uplizna in NMOSD, IgG4-RD and gMG
On 11 December 2025 the EMA’s CHMP issued a positive opinion to extend Uplizna’s (inebilizumab) marketing authorisation to three additional autoimmune conditions: neuromyelitis optica spectrum disorder (NMOSD), immunoglobulin G4‑related disease (IgG4‑RD) and generalized myasthenia gravis (gMG). The recommendation designates Uplizna as monotherapy for...
European Survey Highlights Gaps in Care for Women with Hormonal Migraine
A European Migraine and Headache Alliance survey of 5,410 women revealed major gaps in diagnosing and treating hormonally linked migraine. Forty‑two percent of respondents had never received a formal diagnosis, and 35% reported that doctors never discussed their symptoms. While...
MIT Researchers Develop Self-Implanting Nanotech Brain Devices
MIT Media Lab researchers have created subcellular‑sized wireless bioelectronic devices, termed “circulatronics,” that hitch a ride on monocytes to traverse the bloodstream, cross the blood‑brain barrier, and autonomously implant in inflamed brain tissue. In mouse studies the implants self‑positioned, were...
New Research Findings Challenge Old Beliefs About Myelin Repair in MS
Researchers using advanced imaging in mice discovered that oligodendrocyte precursor cells continuously differentiate into mature oligodendrocytes across the brain and spinal cord, regardless of myelin injury. This overturns the long‑standing belief that these cells only mature in response to damage....
Champion Insights Opens Nationwide Enrolment to Study ALS Risk in High-Performance Groups
Champion Insights has launched a nationwide enrollment to recruit up to 500 elite athletes, military veterans and first responders for a study investigating their elevated risk of amyotrophic lateral sclerosis (ALS). The remote study will collect blood samples and online...
Cure Parkinson’s Expands Its Research Committee and Welcomes New Interns
Cure Parkinson’s has expanded its Research Committee by adding eight new members from leading UK and European institutions, spanning neurology, bioinformatics, pharmacology and more. The charity also welcomed three early‑career researchers as interns, extending the programme beyond the UK to...
Five-Year Data Show Sustained Benefits with Briumvi in Relapsing MS
Long‑term data from the Phase 3 ULTIMATE I and II trials show that continuous treatment with Briumvi (ublituximab) provides sustained clinical benefits for relapsing multiple sclerosis over five years. More than 80 % of patients who started Briumvi remained free of relapses and...